Association between serum uric acid and new onset and progression of chronic kidney disease in a Japanese general population: Iki epidemiological study of atherosclerosis and chronic kidney disease.
Chronic kidney disease
Cohort study
Hyperuricemia
Serum uric acid
Journal
Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
29
06
2020
accepted:
26
02
2021
pubmed:
11
3
2021
medline:
15
12
2021
entrez:
10
3
2021
Statut:
ppublish
Résumé
Although several risk factors for chronic kidney disease (CKD) have been proposed, it remains unclear whether elevated serum uric acid (SUA) is negatively association with kidney function. The aim of this study was to elucidate the association between SUA and new onset and progression of CKD in a Japanese general population. This was a population-based retrospective cohort study using annual health checkup data of residents of Iki Island. A total of 5,507 adults (979 with CKD and 4,528 without) were included. The outcomes were new onset of CKD among participants without CKD at baseline, and progression of CKD among those with CKD. A Cox proportional hazards model was used to evaluate the association between SUA and new onset and progression of CKD. During mean follow-up of 4.6 years, 757 cases of new onset of CKD and 193 with progression of CKD were observed. SUA was significantly associated with new onset of CKD (adjusted hazard ratio 1.13, [95% confidence interval 1.03-1.24] per standard deviation [SD] increase in SUA). In contrast, SUA was not significantly associated with progression of CKD (hazard ratio 1.08, [0.92-1.27] per SD increase). Similar results were obtained when classifying uric acid as categorical. SUA was significantly associated with increased risk for new onset of CKD, but not with progression of CKD among a Japanese general population.
Sections du résumé
BACKGROUND
BACKGROUND
Although several risk factors for chronic kidney disease (CKD) have been proposed, it remains unclear whether elevated serum uric acid (SUA) is negatively association with kidney function. The aim of this study was to elucidate the association between SUA and new onset and progression of CKD in a Japanese general population.
METHODS
METHODS
This was a population-based retrospective cohort study using annual health checkup data of residents of Iki Island. A total of 5,507 adults (979 with CKD and 4,528 without) were included. The outcomes were new onset of CKD among participants without CKD at baseline, and progression of CKD among those with CKD. A Cox proportional hazards model was used to evaluate the association between SUA and new onset and progression of CKD.
RESULTS
RESULTS
During mean follow-up of 4.6 years, 757 cases of new onset of CKD and 193 with progression of CKD were observed. SUA was significantly associated with new onset of CKD (adjusted hazard ratio 1.13, [95% confidence interval 1.03-1.24] per standard deviation [SD] increase in SUA). In contrast, SUA was not significantly associated with progression of CKD (hazard ratio 1.08, [0.92-1.27] per SD increase). Similar results were obtained when classifying uric acid as categorical.
CONCLUSION
CONCLUSIONS
SUA was significantly associated with increased risk for new onset of CKD, but not with progression of CKD among a Japanese general population.
Identifiants
pubmed: 33689045
doi: 10.1007/s10157-021-02042-7
pii: 10.1007/s10157-021-02042-7
doi:
Substances chimiques
Uric Acid
268B43MJ25
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
751-759Subventions
Organisme : Japan Society for the Promotion of Science London
ID : 18K17404
Organisme : Japan Society for the Promotion of Science
ID : 19H03912
Références
Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–72.
doi: 10.1016/S0140-6736(13)60687-X
Japanese Society of Nephrology. Evidence-based Clinical Practice Guideline for CKD 2018. tokyo igakusha; 2018.
Sud M, Tangri N, Pintilie M, Levey AS, Naimark D. Risk of end-stage renal disease and death after cardiovascular events in chronic kidney disease. Circulation. 2014;130:458–65.
doi: 10.1161/CIRCULATIONAHA.113.007106
Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339–52.
doi: 10.1016/S0140-6736(13)60595-4
Braun LA, Sood V, Hogue S, Lieberman B, Copley-Merriman C. High burden and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc Dis. 2012;5:151–63.
pubmed: 23293534
pmcid: 3534533
Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, et al. Hypertension awareness, treatment, and control in adults with ckd: results from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis. 2010;55:441–51.
doi: 10.1053/j.ajkd.2009.09.014
El Minshawy O, Ghabrah T, El Bassuoni E. Diabetic nephropathy as a cause of end-stage renal disease in Tabuk area, Saudi Arabia: a four-year study. Saudi J Kidney Dis Transpl. 2014;25:1105–9.
doi: 10.4103/1319-2442.139967
Janssen WM, de Jong PE, de Zeeuw D. Hypertension and renal disease: role of microalbuminuria. J Hypertens Suppl. 1996;14:S173–7.
doi: 10.1097/00004872-199602000-00004
Johnson RJ, Nakagawa T, Jalal D, Gabriela Sánchez-Lozada L, Kang D-H, Ritz E. Full reviews uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transpl. 2013;28:2221–8.
doi: 10.1093/ndt/gft029
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2012;2013(3):1–150.
Japanese Society of gout and Nucleic Acid Metabolism (2019) Guideline for the management of hyperuricemia and gout. Shindan to chiryo sha.
de Cosmo S, Viazzi F, Pacilli A, Giorda C, Ceriello A, Gentile S, et al. Serum uric acid and risk of CKD in type 2 diabetes. Clin J Am Soc Nephrol. 2015;10:1921–9.
doi: 10.2215/CJN.03140315
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
doi: 10.1053/j.ajkd.2008.12.034
Levey AS, De Jong PE, Coresh J, El NM, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17–28.
doi: 10.1038/ki.2010.483
Nagai K, Yamagata K. Quantitative evaluation of proteinuria for health checkups is more efficient than the dipstick method. Clin Exp Nephrol. 2015;19:152–3.
doi: 10.1007/s10157-014-1034-6
The Japanese Society of Hypertension. Guideline for the management of hypertension. Life science; 2019.
Matsuzawa Y. New criteria for `obesity disease’ in Japan. Circ J. 2002;66:987–92.
doi: 10.1253/circj.66.987
The Japan Diabetes Society. Management of diabetes 2016–2017. Bunkōdō. 2016.
Japan Atherosclerosis society. Guidelines for prevention of atherosclerotic cardiovascular disease 2017. 2017.
Kawashima M, Wada K, Ohta H, Terawaki H, Aizawa Y. Association between asymptomatic hyperuricemia and new-onset chronic kidney disease in Japanese male workers: a long-term retrospective cohort study. BMC Nephrol. 2011;12:31.
doi: 10.1186/1471-2369-12-31
Mok Y, Lee SJ, Kim MS, Cui W, Moon YM, Jee SH. Serum uric acid and chronic kidney disease: the Severance cohort study. Nephrol Dial Transplant. 2012;27:1831–5.
doi: 10.1093/ndt/gfr530
Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19:2407–13.
doi: 10.1681/ASN.2008010080
Oh TR, Choi HS, Kim CS, Bae EH, Ma SK, Sung SA, et al. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study. Sci Rep. 2019;9:6681.
doi: 10.1038/s41598-019-43241-3
Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53:796–803.
doi: 10.1053/j.ajkd.2008.12.021
Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382:2504–13.
doi: 10.1056/NEJMoa1915833
Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, et al. Febuxostat therapy for patients with stage 3 ckd and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018;72:798–810.
doi: 10.1053/j.ajkd.2018.06.028
Koye DN, Magliano DJ, Reid CM, Jepson C, Feldman HI, Herman WH, et al. Risk of progression of nonalbuminuric CKD to end-stage kidney disease in people with diabetes: the CRIC (chronic renal insufficiency cohort) study. Am J Kidney Dis. 2018;72:653–61.
doi: 10.1053/j.ajkd.2018.02.364
Yamanouchi M, Furuichi K, Hoshino J, Toyama T, Hara A, Shimizu M, et al. Nonproteinuric versus proteinuricphenotypesindiabetic kidney disease: a propensity score–matched analysis of a nationwide, biopsy-based cohort study. Diabetes Care. 2019;42:891–902.
doi: 10.2337/dc18-1320
Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44:642–50.
doi: 10.1016/S0272-6386(04)00934-5
Matsukuma Y, Masutani K, Tanaka S, Tsuchimoto A, Fujisaki K, Torisu K, et al. A J-shaped association between serum uric acid levels and poor renal survival in female patients with IgA nephropathy. Hypertens Res. 2017;40:291–7.
doi: 10.1038/hr.2016.134
Yang Y, Zhou W, Wang YW, Zhou R. Gender-specific association between uric acid level and chronic kidney disease in the elderly health checkup population in China. Ren Fail. 2019;41:197–203.
doi: 10.1080/0886022X.2019.1591994
Yu MA, Sánchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 2010;28:1234–42.
doi: 10.1097/HJH.0b013e328337da1d
Jalal DI, Chonchol M, Chen W, Targher G. Uric Acid as a Target of Therapy in CKD. Am J Kidney Dis. 2013;61:134–46.
doi: 10.1053/j.ajkd.2012.07.021